Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ankk1 schizophrenia:

Identification of ANKK1 rs1800497 variant in schizophrenia: new data and meta-analysis. Zhang C et al. Am J Med Genet B Neuropsychiatr Genet. (2014)

Association between ANKK1 (rs1800497) and LTA (rs909253) Genetic Variants and Risk of Schizophrenia. Arab AH et al. Biomed Res Int. (2015)

Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism. Kunii Y et al. Prog Neuropsychopharmacol Biol Psychiatry. (2014)

Search results

Items: 1 to 20 of 27

1.

[The interaction effect of ANKK1/DRD2 TaqIA and HTR2C Cys23Ser on approach motivation in schizophrenic patients and normals].

Alfimova MV, Korovaitseva GI, Lezheiko TV, Golubev SA, Snegireva AA, Sakharova EA, Golimbet VE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(7):67-72. doi: 10.17116/jnevro20181187167. Russian.

PMID:
30132460
2.

The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).

Kurylev AA, Brodyansky VM, Andreev BV, Kibitov AO, Limankin OV, Mosolov SN.

Psychiatr Danub. 2018 Jun;30(2):157-163. doi: 10.24869/psyd.2018.157.

3.

Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.

Pinto JAF, Freitas PHB, Nunes FDD, Granjeiro PA, Santos LLD, Machado RM.

Rev Lat Am Enfermagem. 2018;26:e2983. doi: 10.1590/1518-8345.2222.2983. Epub 2018 May 17. Portuguese, Spanish, English.

4.

DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study.

Miura I, Kunii Y, Hino M, Hoshino H, Matsumoto J, Kanno-Nozaki K, Horikoshi S, Kaneko H, Bundo M, Iwamoto K, Yabe H.

J Psychiatr Res. 2018 May;100:84-87. doi: 10.1016/j.jpsychires.2018.02.018. Epub 2018 Feb 23.

PMID:
29499474
5.

[A role of interactions between N-methyl-D-aspartate and dopamine receptors in facial emotion recognition impairment in schizophrenia].

Alfimova MV, Golimbet VE, Korovaitseva GI, Lezheiko TV, Tikhonov DV, Ganisheva TK, Berezin NB, Snegireva AA, Shemiakina TK.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6):47-52. doi: 10.17116/jnevro20171176147-52. Russian.

PMID:
28745671
6.

Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia.

Nkam I, Ramoz N, Breton F, Mallet J, Gorwood P, Dubertret C.

PLoS One. 2017 Jan 13;12(1):e0170147. doi: 10.1371/journal.pone.0170147. eCollection 2017.

7.

Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM.

J Psychiatr Res. 2017 Mar;86:9-17. doi: 10.1016/j.jpsychires.2016.11.007. Epub 2016 Nov 17.

8.

Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status.

Eisenstein SA, Bogdan R, Love-Gregory L, Corral-Frías NS, Koller JM, Black KJ, Moerlein SM, Perlmutter JS, Barch DM, Hershey T.

Synapse. 2016 Oct;70(10):418-31. doi: 10.1002/syn.21916. Epub 2016 Jun 17.

9.

Association between ANKK1 (rs1800497) and LTA (rs909253) Genetic Variants and Risk of Schizophrenia.

Arab AH, Elhawary NA.

Biomed Res Int. 2015;2015:821827. doi: 10.1155/2015/821827. Epub 2015 May 31.

10.

Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis.

Yao J, Pan YQ, Ding M, Pang H, Wang BJ.

Am J Med Genet B Neuropsychiatr Genet. 2015 Jan;168B(1):1-13. doi: 10.1002/ajmg.b.32281. Epub 2014 Dec 12. Review.

PMID:
25504812
11.

Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Bishop JR, Reilly JL, Harris MS, Patel SR, Kittles R, Badner JA, Prasad KM, Nimgaonkar VL, Keshavan MS, Sweeney JA.

Psychopharmacology (Berl). 2015 Jan;232(1):145-54. doi: 10.1007/s00213-014-3649-4. Epub 2014 Aug 7.

12.

Identification of ANKK1 rs1800497 variant in schizophrenia: new data and meta-analysis.

Zhang C, Zhang J, Fan J, Cheng W, Du Y, Yu S, Fang Y.

Am J Med Genet B Neuropsychiatr Genet. 2014 Oct;165B(7):564-71. doi: 10.1002/ajmg.b.32259. Epub 2014 Jul 30.

PMID:
25073965
13.

Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism.

Kunii Y, Miura I, Matsumoto J, Hino M, Wada A, Niwa S, Nawa H, Sakai M, Someya T, Takahashi H, Kakita A, Yabe H.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:123-8. doi: 10.1016/j.pnpbp.2014.03.014. Epub 2014 Apr 3.

PMID:
24704945
14.

DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.

Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K, Voisey J, Morris CP, Nyst P, Noble EP, Young RM.

J Psychopharmacol. 2013 Apr;27(4):343-8. doi: 10.1177/0269881112463469. Epub 2012 Oct 31.

PMID:
23118020
15.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
16.

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.

Giegling I, Balzarro B, Porcelli S, Schäfer M, Hartmann AM, Friedl M, Konte B, Krämer P, Möller HJ, De Ronchi D, Stassen HH, Serretti A, Rujescu D.

Eur Arch Psychiatry Clin Neurosci. 2013 Feb;263(1):65-74. doi: 10.1007/s00406-012-0348-1. Epub 2012 Aug 15.

PMID:
22893251
17.

Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.

Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, Bieńkowski P, Mierzejewski P, Potemkowski A, Samochowiec J.

Pharmacol Rep. 2012;64(3):528-35.

18.

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.

Lee ST, Ryu S, Kim SR, Kim MJ, Kim S, Kim JW, Lee SY, Hong KS.

J Clin Psychopharmacol. 2012 Aug;32(4):441-8. doi: 10.1097/JCP.0b013e31825ac35c.

PMID:
22722500
19.

Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach.

Völter C, Riedel M, Wöstmann N, Aichert DS, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, Ettinger U.

Int J Neuropsychopharmacol. 2012 Nov;15(10):1427-40. doi: 10.1017/S1461145711001787. Epub 2012 Jan 16.

20.

[ANKK1 gene in psychiatry].

Suchanecka A, Grzywacz A, Samochowiec J.

Psychiatr Pol. 2011 May-Jun;45(3):349-56. Review. Polish.

PMID:
22232965

Supplemental Content

Loading ...
Support Center